Synopsis:
The planned medac breakfast symposium “Improving conventional therapy for patients with rheumatoid arthritis by subcutaneous MTX” will elaborate on the therapeutic strategies in the first-line setting for patients with rheumatoid arthritis (RA).
Methotrexate (MTX) is a well-known, disease-modifying antirheumatic drug (DMARD) used primarily as first-line therapy in the treatment of patients with RA. A randomized clinical trial showed that subcutaneous (SC) MTX was more effective and better tolerated than oral MTX over a long-term treatment period in a Japanese population (Tanaka et al 2022). Higher ACR20 response rates and fewer adverse events, particularly gastrointestinal adverse events, were observed. Subcutaneous MTX is a favorable option for Japanese patients with RA. SC MTX is recommended with superior efficacy and equivalent or better safety compared to oral MTX in the latest Rheumatoid Arthritis Practice Guidelines in Japan (JCR: Japan College of Rheumatology) in 2024.
Agenda:
|
|
Chairperson: Prof. Yoshiya Tanaka
|
|
08:30 |
Welcome Remarks: Introduction
|
|
08:31 |
Importance of early subcutaneous
metoject in RA therapy
Prof. Yoshiya Tanaka , , PD Dr. Eva Schwaneck |
|
08:35 |
Clinical studies of early subcutaneous metoject in Japanease patients
Prof. Kunihiro Yamaoka |
|
08:50 |
Initiation RA therapy: comparison of subcutaneous versus oral MTX and its impact
PD Dr. Eva Schwaneck |
|
09:05 |
Discussion and relevance for the daily routine
Prof. Yoshiya Tanaka |
